12:00 AM
Jun 03, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tafinlar dabrafenib: Interim Phase I/II data

Interim data from 147 metastatic melanoma patients with V600 BRAF mutations in an open-label, dose-escalation, U.S. and Australian Phase I/II trial showed that twice-daily 150 mg Tafinlar plus once-daily 2 mg Mekinist trametinib led to a median progression-free survival (PFS) of 10.8 months in BRAF inhibitor-naïve patients in part B of the trial (n=24) and 9.4 months in BRAF inhibitor-naïve patients in part C of the trial (n=54). Tafinlar plus Mekinist led to a median PFS of 3.6 months in BRAF inhibitor-resistant patients in both part B (n=26) and part C (n=43) of the trial. In BRAF-inhibitor...

Read the full 472 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >